What type of study is this?

October 16, 2025Open Access

Low-Intensity Pretransplant Therapy in Acute Myeloid Leukemia: A 13-Year Single-Center Experience

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals non-relapse mortality rates in AML patients undergoing allo-HCT, suggesting potential for broader eligibility.

One-year non-relapse mortality for hypomethylating agent patients was 26.2%, significantly higher than 4.2% for HMA plus venetoclax patients.
Three-year overall survival rates were 47.6% for HMA, 61.7% for HMA plus venetoclax, and 71.8% for upfront therapy.
The study analyzed outcomes from 106 AML patients undergoing allo-HCT between 2010 and 2023, regardless of remission status.
Findings suggest that allo-HCT is feasible in AML patients using low-intensity pretransplant regimens, emphasizing the need for further trials.

Wehr et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis reveals non-relapse mortality rates in AML patients undergoing allo-HCT, suggesting potential for broader eligibility.